Theravance Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	288.1	167.81	37.8	39.55	298.17	89.96
Short-Term Investments	106.57	147.55	50.55	62.88	29.31	83.51
Cash & Short-Term Investments	394.67	315.36	88.35	102.43	327.48	173.47
Cash Growth	201.61%	256.94%	-13.74%	-68.72%	88.79%	-40.78%
Accounts Receivable	15.58	95.54	68.44	17.47	16.79	14.07
Total Trade Receivables	15.58	95.54	68.44	17.47	16.79	14.07
Other Current Assets	7.38	7.56	4.28	13.64	9.2	62.34
Total Current Assets	417.63	418.46	161.07	133.54	353.46	249.87
Net Property, Plant & Equipment	28.54	30.27	35.77	45.36	52	53.35
Long-Term Investments	-	11.13	-	-	-	-
Other Long-Term Assets	26.14	25.72	157.32	203.1	201.94	71.6
Total Assets	472.31	485.57	354.16	382	607.4	374.82
Accounts Payable	1.1	2.57	2.24	1.52	1.55	3.1
Accrued Expenses	19.92	24.79	19.13	12.83	20.41	35.25
Current Portion of Long-Term Debt	-	-	-	-	-	16.94
Current Portion of Leases	10.75	10.95	10.71	3.92	6.75	0.5
Unearned Revenue	-	-	-	-	-	0.1
Other Current Liabilities	-	-	-	6.49	-	2.69
Total Current Liabilities	31.78	38.3	32.09	24.77	28.72	58.59
Long-Term Debt	-	-	-	-	-	599.39
Long-Term Leases	29.75	31.76	39.11	45.24	45.41	52.68
Other Long-Term Liabilities	120.19	118.79	107.42	99	91.48	2.73
Total Long-Term Liabilities	149.94	150.55	146.53	144.24	136.89	654.81
Total Liabilities	181.72	188.85	178.62	169	165.6	713.39
Common Stock	0	0	-	-	0	0
Additional Paid-in Capital	1,155	1,156	1,141	1,122	1,296	1,387
Accumulated Other Comprehensive Income	-0.06	0.06	0.01	-0.07	-0.02	-
Retained Earnings	-864.56	-859.63	-965.52	-909.1	-853.91	-1,726
Shareholders' Equity	290.59	296.72	175.55	213	441.8	-338.57
Total Liabilities & Equity	472.31	485.57	354.16	382	607.4	374.82
Total Debt	40.5	42.7	49.82	49.16	52.16	669.52
Net Cash (Debt)	354.16	272.65	38.53	53.27	275.32	-496.05
Net Cash Growth	328.25%	607.64%	-27.67%	-80.65%	-	-
Net Cash Per Share	6.83	5.29	0.79	0.96	3.74	-7.14
Book Value	290.59	296.72	175.55	213	441.8	-338.57
Book Value Per Share	5.60	5.76	3.59	3.85	6.00	-4.87
Tangible Book Value	290.59	296.72	175.55	213	441.8	-338.57
Tangible Book Value Per Share	5.60	5.76	3.59	3.85	6.00	-4.87

SEC Filings: 10-K · 10-Q